Algert Global LLC boosted its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 33.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 341,158 shares of the medical research company’s stock after purchasing an additional 86,138 shares during the quarter. Algert Global LLC owned about 0.72% of Enzo Biochem worth $1,406,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in Enzo Biochem by 8.5% in the second quarter. BlackRock Inc. now owns 3,993,660 shares of the medical research company’s stock valued at $20,729,000 after purchasing an additional 313,826 shares during the period. Renaissance Technologies LLC grew its holdings in Enzo Biochem by 0.8% in the second quarter. Renaissance Technologies LLC now owns 3,002,200 shares of the medical research company’s stock valued at $15,581,000 after purchasing an additional 25,300 shares during the period. Dimensional Fund Advisors LP grew its holdings in Enzo Biochem by 2.0% in the third quarter. Dimensional Fund Advisors LP now owns 2,042,601 shares of the medical research company’s stock valued at $8,415,000 after purchasing an additional 40,030 shares during the period. Northern Trust Corp grew its holdings in Enzo Biochem by 7.1% in the second quarter. Northern Trust Corp now owns 545,989 shares of the medical research company’s stock valued at $2,834,000 after purchasing an additional 36,237 shares during the period. Finally, Marathon Capital Management grew its holdings in Enzo Biochem by 13.5% in the third quarter. Marathon Capital Management now owns 405,046 shares of the medical research company’s stock valued at $1,668,000 after purchasing an additional 48,242 shares during the period. Hedge funds and other institutional investors own 66.78% of the company’s stock.
Separately, TheStreet downgraded shares of Enzo Biochem from a “c-” rating to a “d+” rating in a report on Wednesday, October 17th.
Enzo Biochem stock opened at $3.23 on Friday. Enzo Biochem, Inc. has a 1 year low of $2.95 and a 1 year high of $9.48.
Enzo Biochem (NYSE:ENZ) last released its earnings results on Tuesday, October 16th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $24.46 million during the quarter. Enzo Biochem had a negative net margin of 9.86% and a negative return on equity of 13.25%.
In other Enzo Biochem news, Director Bruce A. Hanna purchased 15,000 shares of Enzo Biochem stock in a transaction on Thursday, October 18th. The shares were purchased at an average cost of $3.52 per share, with a total value of $52,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elazar Rabbani purchased 10,000 shares of Enzo Biochem stock in a transaction on Monday, October 29th. The shares were acquired at an average cost of $3.35 per share, for a total transaction of $33,500.00. Following the completion of the transaction, the insider now owns 1,848,668 shares of the company’s stock, valued at $6,193,037.80. The disclosure for this purchase can be found here. Insiders own 9.40% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.